Allogeneic, or off-the-shelf, cell therapies derived from induced pluripotent stem cells (iPSCs) can be produced in a consistent, scalable manner and can significantly expand the availability and promise of this potentially curative modality. Although only autologous versions are currently approved, cell therapies are becoming an important alternative for treating many relapsed/refractory cancers and show substantial…

Branford, Connecticut–based Isoplexis (NSDQ:ISO) made its public market debut today with an initial public offering of 8,333,000 shares of common stock initially priced at $15 per share. ISO shares ended up selling for $11.52 apiece at the end of trading, equating to $96 million (less fees and expenses associated with the IPO). That was 23%…